Literature DB >> 25677591

Aptamers and their applications in nanomedicine.

Hongguang Sun1, Youli Zu1.   

Abstract

Aptamers are composed of short RNA or single-stranded DNA sequences that, when folded into their unique 3D conformation, can bind to their targets with high specificity and affinity. Although functionally similar to protein antibodies, oligonucleotide aptamers offer several advantages over protein antibodies in biomedical and clinical applications. Through the enhanced permeability and retention effect, nanomedicines can improve the therapeutic index of a treatment and reduce side effects by enhancing accumulation at the disease site. However, this targets tumors passively and, thus, may not be ideal for targeted therapy. To construct ligand-directed "active targeting" nanobased delivery systems, aptamer-equipped nanomedicines have been tested for in vitro diagnosis, in vivo imaging, targeted cancer therapy, theranostic approaches, sub-cellular molecule detection, food safety, and environmental monitoring. This review focuses on the development of aptamer-conjugated nanomedicines and their application for in vivo imaging, targeted therapy, and theranostics.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  active targeting; aptamers; combinational therapy; nanomedicine; on-command release system

Mesh:

Substances:

Year:  2015        PMID: 25677591      PMCID: PMC4441590          DOI: 10.1002/smll.201403073

Source DB:  PubMed          Journal:  Small        ISSN: 1613-6810            Impact factor:   13.281


  107 in total

1.  Construction and selection of bead-bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries designed for rapid PCR-based sequencing.

Authors:  Xianbin Yang; Suzanne E Bassett; Xin Li; Bruce A Luxon; Norbert K Herzog; Robert E Shope; Judy Aronson; Tarl W Prow; James F Leary; Romy Kirby; Andrew D Ellington; David G Gorenstein
Journal:  Nucleic Acids Res       Date:  2002-12-01       Impact factor: 16.971

Review 2.  Nanomedicine(s) under the microscope.

Authors:  Ruth Duncan; Rogerio Gaspar
Journal:  Mol Pharm       Date:  2011-10-26       Impact factor: 4.939

3.  A hybrid DNA aptamer-dendrimer nanomaterial for targeted cell labeling.

Authors:  Jing Zhou; Boonchoy Soontornworajit; Jacob Martin; Bruce A Sullenger; Eli Gilboa; Yong Wang
Journal:  Macromol Biosci       Date:  2009-09-09       Impact factor: 4.979

4.  In vitro selection of DNA aptamers to anthrax spores with electrochemiluminescence detection.

Authors:  J G Bruno; J L Kiel
Journal:  Biosens Bioelectron       Date:  1999-05-31       Impact factor: 10.618

5.  Targeting cancer cells with controlled release nanocapsules based on a single aptamer.

Authors:  Frank J Hernandez; Luiza I Hernandez; Alessandro Pinto; Thomas Schäfer; Veli C Özalp
Journal:  Chem Commun (Camb)       Date:  2013-01-08       Impact factor: 6.222

6.  Application of locked nucleic acids to improve aptamer in vivo stability and targeting function.

Authors:  Kathrin S Schmidt; Sandra Borkowski; Jens Kurreck; Andrew W Stephens; Rolf Bald; Maren Hecht; Matthias Friebe; Ludger Dinkelborg; Volker A Erdmann
Journal:  Nucleic Acids Res       Date:  2004-10-27       Impact factor: 16.971

7.  Highly efficient inhibition of human immunodeficiency virus type 1 reverse transcriptase by aptamers functionalized gold nanoparticles.

Authors:  Yen-Chun Shiang; Chung-Mao Ou; Shih-Ju Chen; Ting-Yu Ou; Han-Jia Lin; Chih-Ching Huang; Huan-Tsung Chang
Journal:  Nanoscale       Date:  2013-04-07       Impact factor: 7.790

Review 8.  Nanoparticle therapeutics: an emerging treatment modality for cancer.

Authors:  Mark E Davis; Zhuo Georgia Chen; Dong M Shin
Journal:  Nat Rev Drug Discov       Date:  2008-09       Impact factor: 84.694

9.  Aptamer-functionalized, ultra-small, monodisperse silica nanoconjugates for targeted dual-modal imaging of lymph nodes with metastatic tumors.

Authors:  Li Tang; Xujuan Yang; Lawrence W Dobrucki; Isthier Chaudhury; Qian Yin; Catherine Yao; Stéphane Lezmi; William G Helferich; Timothy M Fan; Jianjun Cheng
Journal:  Angew Chem Int Ed Engl       Date:  2012-11-07       Impact factor: 15.336

Review 10.  Immunomodulation of nanoparticles in nanomedicine applications.

Authors:  Qing Jiao; Liwen Li; Qingxin Mu; Qiu Zhang
Journal:  Biomed Res Int       Date:  2014-05-20       Impact factor: 3.411

View more
  37 in total

Review 1.  Aptahistochemistry in diagnostic pathology: technical scrutiny and feasibility.

Authors:  Bakhtiar A Bukari; Marimuthu Citartan; Ewe Seng Ch'ng; Mawethu P Bilibana; Timofey Rozhdestvensky; Thean-Hock Tang
Journal:  Histochem Cell Biol       Date:  2017-03-20       Impact factor: 4.304

2.  Self-Assembled Aptamer-Nanomedicine for Targeted Chemotherapy and Gene Therapy.

Authors:  Nianxi Zhao; Zihua Zeng; Youli Zu
Journal:  Small       Date:  2017-12-04       Impact factor: 13.281

3.  DNA nanotechnology for nucleic acid analysis: multifunctional molecular DNA machine for RNA detection.

Authors:  A J Cox; H N Bengtson; K H Rohde; D M Kolpashchikov
Journal:  Chem Commun (Camb)       Date:  2016-12-06       Impact factor: 6.222

Review 4.  The delivery of therapeutic oligonucleotides.

Authors:  Rudolph L Juliano
Journal:  Nucleic Acids Res       Date:  2016-04-15       Impact factor: 16.971

5.  Aptamer-Targeted Drug Delivery for Staphylococcus aureus Biofilm.

Authors:  Pernille Ommen; Line Hansen; Bente K Hansen; Hieu Vu-Quang; Jørgen Kjems; Rikke L Meyer
Journal:  Front Cell Infect Microbiol       Date:  2022-04-29       Impact factor: 6.073

6.  Aptamer-armed nanostructures improve the chemotherapy outcome of triple-negative breast cancer.

Authors:  Quanyuan Wan; Zihua Zeng; Jianjun Qi; Zhenghu Chen; Xiaohui Liu; Youli Zu
Journal:  Mol Ther       Date:  2022-02-08       Impact factor: 12.910

Review 7.  Aptamers: versatile molecular recognition probes for cancer detection.

Authors:  Hongguang Sun; Weihong Tan; Youli Zu
Journal:  Analyst       Date:  2016-01-21       Impact factor: 4.616

Review 8.  RNA-based therapeutics for colorectal cancer: Updates and future directions.

Authors:  Jingwen Liu; Bin Guo
Journal:  Pharmacol Res       Date:  2019-12-19       Impact factor: 7.658

9.  Tumour-Targeted and Redox-Responsive Mesoporous Silica Nanoparticles for Controlled Release of Doxorubicin and an siRNA Against Metastatic Breast Cancer.

Authors:  Jialang Zhuang; Siqi Chen; Ye Hu; Fan Yang; Qin Huo; Ni Xie
Journal:  Int J Nanomedicine       Date:  2021-03-08

Review 10.  Bone site-specific delivery of siRNA.

Authors:  Xinli Liu
Journal:  J Biomed Res       Date:  2015-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.